Jpmorgan Chase & CO Sorrento Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.17 - $1.19 $525,499 - $3.68 Million	-3,091,176 Reduced 100.0%	1 $0
Q4 2022 Feb 13, 2023	BUY	$0.74 - $1.83 $46,859 - $115,881	63,323 Added 2.09%	3,091,177 $2.74 Million
Q3 2022 Nov 14, 2022	SELL	$1.51 - $2.88 $364,186 - $694,607	-241,183 Reduced 7.38%	3,027,854 $4.75 Million
Q2 2022 Aug 11, 2022	SELL	$1.24 - $2.33 $36,036 - $67,714	-29,062 Reduced 0.88%	3,269,037 $6.57 Million
Q1 2022 May 11, 2022	SELL	$2.0 - $4.9 $552,436 - $1.35 Million	-276,218 Reduced 7.73%	3,298,099 $7.68 Million
Q4 2021 Feb 10, 2022	BUY	$4.65 - $7.23 $2.97 Million - $4.62 Million	639,306 Added 21.78%	3,574,317 $16.6 Million
Q3 2021 Nov 12, 2021	BUY	$7.41 - $10.99 $21.7 Million - $32.3 Million	2,935,011 New	2,935,011 $22.4 Million

5.53M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.